-transparent.png){kind=logo}
A direct 2 stage enzymatic test and the direct anti gamma globulin test were used to predict hemolytic disease of the newborn. Maternal allo-antibodies were determined in cord blood of all newborns from April to June 1988. 0.25% bromelase was used for the 2 Stage Enzymatic Test and a polyspecific anti-gammaglobulin serum was used for the Anti Gamma Globulin Test. Of 618 newborns 97 had parental ABO heterospecificity. Maternal allo-antibodies were present in 20 cases (3.2%). 20 of 86 fullterm newborns developed jaundice presumably due to ABO incompatibility. Blood exchange was required in 6, while phototherapy was sufficient in the rest. The 2 Stage Enzymatic Test was positive in 20 of these cases and the Anti Gamma Globulin Test was positive in 10. Thus, these tests may be used to predict hemolytic disease of the newborn due to ABO incompatibility.
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
January 1955,
Revista chilena de pediatria,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
June 1953,
A.M.A. American journal of diseases of children,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
December 1956,
The Journal of the Indiana State Medical Association,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
January 1959,
Hawaii medical journal,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
January 1974,
Vox sanguinis,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
July 1957,
Ceskoslovenska pediatrie,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
December 1956,
Minerva pediatrica,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
August 1977,
Zeitschrift fur Geburtshilfe und Perinatologie,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
January 1966,
Bibliotheca gynaecologica,
C Arévalo, and
F Herrmann, and
E Aguirre, and
J Vera
January 1959,
Revista cubana de pediatria,
